Ceribell (CBLL) Cash from Financing Activities (2023 - 2026)
Ceribell (CBLL) posted Cash from Financing Activities of $1.6 million for Q1 2026, up 16.32% on a QoQ basis from $1.4 million in Q4 2025, and up 81500.0% year-over-year from N/an in Q1 2025.
Ceribell (CBLL) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Ceribell's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 81500.0% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 96.46% YoY) and the FY2025 annual result came in at $5.1 million, down 97.43% from the prior year.
- Cash from Financing Activities was $1.6 million for Q1 2026 at Ceribell, up from $1.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $190.7 million in Q4 2024 and bottomed at -$3.5 million in Q4 2023.
- A 4-year average of $20.0 million and a median of $1.5 million in 2025 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 100400.0% in 2025, while the deepest fall reached 99.97% in 2025.
- Ceribell's Cash from Financing Activities stood at -$3.5 million in 2023, then soared by 5609.19% to $190.7 million in 2024, then slumped by 99.26% to $1.4 million in 2025, then grew by 16.32% to $1.6 million in 2026.
- Business Quant data shows CBLL's Cash from Financing Activities at $1.6 million in Q1 2026, $1.4 million in Q4 2025, and $1.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Ceribell | 613.16 Mn | 471.97 Mn | 23.12 Mn | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.63 Mn |
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 190.73 Mn |
| Dec 31, 2024 | 190.73 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 7.68 Mn |
| Mar 31, 2024 | 7.68 Mn |
| Dec 31, 2023 | -3.46 Mn |
| Dec 31, 2023 | -3.46 Mn |